China Pharma Holdings
CPHI
8 hedge funds and large institutions have $443K invested in China Pharma Holdings in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 6 → 8 (+2)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
1% less capital invested
Capital invested by funds: $446K → $443K (-$3K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$16.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.16K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$2.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20.6K |
| 2 |
VF
Virtu Financial
New York
|
-$7.73K |
CPHI Hedge Fund Activity: Q4 2017 in Review
8 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q4 2017, worth a combined $443K — down 0.67% from $446K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CPHI positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $16.1K. The largest seller was Citadel Advisors, cutting an estimated $20.6K.
- 8 institutional investors held China Pharma Holdings (CPHI) as of Q4 2017, up from 6 in Q3 2017.
- Funds reported $443K of China Pharma Holdings stock for Q4 2017, down 0.67% quarter-over-quarter.
- 2 funds opened new China Pharma Holdings positions in Q4 2017 and 0 closed out, a net change of +2 holders.
- The largest China Pharma Holdings buyer in Q4 2017 was Renaissance Technologies, an estimated $16.1K added.
- The largest China Pharma Holdings seller in Q4 2017 was Citadel Advisors, an estimated $20.6K sold.
Based on aggregated 13F filings for Q4 2017.